China Drug Classification

[membership level=”0,4″][The content continues for paid members only.] Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership] CFDA has announced (in Chinese) a change to its classification system for the registration of new and generic drugs, effective at the beginning of March. The primary change to the system is recognizing that a drug is no longer considered “new” if it has been previously marketed outside of China. The announcement also discusses the definition of innovative drugs, what constitutes a generic drug, and how companies can comply with the new system.
[/membership]